Subject: Imreg Asks NASD To Review 'Shorting' Of Its Class A Shares Date: Published: 12/12/86 43 lines Source: Wall Street Journal. Copyright Dow Jones & Co. Inc. Imreg Asks NASD To Review 'Shorting' Of Its Class A Shares NEW ORLEANS -- Imreg Inc. says it asked the National Association of Securities Dealers to review the appearance of "aggressive shorting" of its Class A stock. A. Arthur Gottlieb, president and chief executive officer of this biotechnology concern, said Imreg seeks to determine whether persons or companies are deliberately trying to "manipulate or artificially depress the market" for their own profit. Last week, the NASD said it found a substantial error in its initial publication of its short-interest list for Imreg. For example, Imreg's short interest was listed at 59,342 shares in November. The correct figures, according to the NASD, should have been 767,892 shares. A NASD official said last week that a business conduct committee will determine whether disciplinary action will be taken against concerns responsible for the inaccurate reporting. But NASD declined to name the concerns. Investors use short interest figures to determine how much short selling is going on in individual stocks. A short sale is a sale of borrowed stock by investors expecting its price to drop. The investors expect to profit on the difference between the price realized in the sale and the cost of replacing the borrowed shares. Imreg recently announced it began its final stage of government-required testing of a drug treatment for acquired immune deficiency syndrome, or AIDS, and a pre-AIDS condition. Imreg's stock, which began the year selling at $20.625, was split on a two-for-one basis in February and has been trading between $9 and $7 in recent weeks. (This article is made available here by Dow Jones Co. for the personal and non-commercial use of callers to this bbs, in the hope that it will be of some help to those who are suffering from the disease and others who are seeking to help them.)